Ginkgo Bioworks Holdings, Inc.

Day range

$9.69 – $10.11

Open

$9.96

Prev close

$9.99

Volume

582.22K

Market cap

$672.73M

Shares out

55.38M

P/E

—

P/S

6.01

P/B

1.60

P/FCF

—

ROE

-69.2%

ROA

-29.4%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Investor presentationJul 30, 2026

  Ginkgo Bioworks Holdings, Inc. (the "Company") announced today that it plans to host a presentation and Q&A session reviewing its business performance for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available at the same link following the session.

• Annual meeting resultsJun 12, 2026

  On June 11, 2026, Ginkgo Bioworks Holdings, Inc. (the "Company") held its 2026 annual meeting of shareholders (the "Annual Meeting")... Pursuant to the foregoing votes, the six nominees listed above were elected to serve on the Company's Board of Directors.

• Business line exitApr 7, 2026

  the Seller contributed to the Purchaser all of the issued and outstanding equity interests of Biosecurity, constituting substantially all of the Company's operations comprising its Biosecurity segment

• Divestiture agreementFeb 27, 2026

  On February 26, 2026, Ginkgo Bioworks, Inc. (the "Seller"), a wholly owned subsidiary Ginkgo Bioworks Holdings, Inc. (the "Company"), entered into a Stock Purchase Agreement (the "Purchase Agreement") with Tower Biosecurity, Inc. (the "Purchaser") and Ginkgo Biosecurity, LLC ("Biosecurity"). Subject to the terms and conditions of the Purchase Agreement, the Seller will contribute to the Purchaser all of the issued and outstanding equity interests of Biosecurity, constituting substantially all of the Company's operations comprising its Biosecurity segment, and in exchange, the Purchaser will issue to the Seller shares of common stock of the Purchaser representing approximately 20% of the issued and outstanding equity of the Purchaser on a fully diluted basis.

• Executive officer appointmentDec 23, 2025

  Jennifer Wipf, who was previously Chief Commercial Officer and General Manager, Discovery Solutions and Manufacturing, will assume responsibilities related to the Company's operations, including day-to-day commercial operations, procurement, deployment, facilities and real estate, and people operations, reporting to Dr. Kelly.

• TWSTTwist Bioscience Corporation Common Stock+4.05%

Days to cover

2.7

Short interest

7.32M

Avg volume

2.74M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know
  negativeZacks Investment Research· Oct 20, 2026
• Here's Why Ginkgo Bioworks Holdings, Inc. (DNA) Fell More Than Broader Market
  negativeZacks Investment Research· Oct 14, 2026
• Ginkgo Bioworks Holdings, Inc. (DNA) Falls More Steeply Than Broader Market: What Investors Need to Know
  negativeZacks Investment Research· Oct 7, 2026
• AI-Driven Innovation Reshapes Vaccine Adjuvant Discovery as Investment Surges Across Public and Private Sectors
  positiveGlobeNewswire Inc.· Sep 24, 2026
• Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
  negativeZacks Investment Research· Sep 23, 2026